Conference Details - Overview
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Defining a Standard of Care for Indolent NHL and CLL: A 2009 Perspective
The Fairmont Orchid
Kohala Coast, HI
June 23, 2009
Conference Overview
Oncology CME-Certified Symposium
This minisymposium is held in conjunction with the 2009 Pan Pacific Lymphoma Conference.
Management of hematologic malignancies, including indolent NHL, MCL, and CLL, remains a clinical challenge due to diversity in presentation, biology, and prognosis. The incorporation of monoclonal antibodies into chemotherapy regimens has dramatically changed the therapeutic landscape in indolent NHL and CLL. However, effective standards of care for many of these B-cell malignancies are still undefined. Moreover, development of refractory disease and toxicity issues with current chemoimmunotherapy regimens limit their long-term use, underscoring the need for more effective regimens. Several clinical efforts are evaluating the safety and efficacy of newer monoclonal antibodies and cytotoxic agents and defining risk-adapted therapies in the context of current treatment options for indolent NHL and CLL; these efforts will be addressed in the Defining a Standard of Care for Indolent NHL and CLL: A 2009 Perspective symposium. Emphasis will be placed on conveying the key findings reported at recent meetings that will most directly impact optimal physician practice. The practical applicability of such evolving clinical trial findings in making treatment decisions for patients with FL and CLL will be debated by key thought leaders in the field.
This activity is part of PER's Integrated Oncology Learning Series: A Focus on Chronic Lymphocytic Leukemia
CME Accreditation and Credit Designation
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is provided for 2.0 contact hours under ANCC criteria. Provided for 2.4 contact hours under Iowa Provider #78. Provider approved by the California Board of Registered Nursing, Provider #13699 for 2.4 contact hours.
This educational program is directed toward medical oncologists specializing in hematologic malignancies. Nurses, fellows, and pharmacists who are interested in the management of hematologic malignancies are also invited to attend.At the conclusion of this symposium, you should be able to:
- Apply cytogenetic information to prognostication for CLL and prediction of treatment success when applicable
- Assess the activity and safety profiles of various agents, including alkylating agents and monoclonal antibodies, used in the treatment of CLL and indolent NHL
- Review current therapeutic options, including chemotherapy and monoclonal antibodies, for relapsed indolent NHL
- Compare the safety and efficacy profiles of R-CHOP to those of novel regimens in the treatment of patients with newly diagnosed indolent NHL
- Discuss current standards of care for relapsed MCL and incorporate newer clinical trial data into treatment options for patients with this disease
Educational Grants
An educational grant for this activity was provided by:
- GlaxoSmithKline
- Cephalon Oncology